Ginkgo disclosed a reduction in force of roughly 35% of its workforce amid restructuring and cost-cutting.
SourceOur mission is to make biology easier to engineer.
Public company, workplace, funding, and market signals
Boston-based public biotechnology company founded in 2008 that builds autonomous labs, robotics/software platforms, and contract R&D services to help customers program biology across biopharma, agriculture, industrial biotech, and government use cases.
Primary product
Autonomous lab platform for biotech R&D (RAC robotics + Catalyst software + Cloud Lab services)
Founded
2008
Headquarters
Boston, Massachusetts, United States
Team size
400-500
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
Synthetic biology / laboratory automation
Offices
18 jobs at Ginkgo Bioworks
Business model
Stage
Public
Total raised
$4.1B
Latest round
Grant · Apr 2024
Leadership
Chief Executive Officer, Co-founder
President, Co-founder
Chief Technology Officer, Co-founder
Head of Strategy, Co-founder
Chief Financial Officer
Founder, Ginkgo Fellow
Engineering-heavy and research-driven, with an autonomy/robotics-first culture, a strong Boston on-site presence, and heavy emphasis on AI-augmented software and high-throughput biological experimentation.
Work style
Onsite
Visa sponsorship
Limited
Compensation
Current public job postings show base salary bands such as $85.6k-$120.2k, $103.9k-$155.5k, and $134.3k-$189.9k depending on role, plus stock awards and a broad benefits package. Several current postings say Ginkgo cannot sponsor or take over H-1B sponsorship for those roles.
Benefits
Pricing
Primarily B2B custom contracts: contract research / R&D service fees, cloud-lab usage, automation system design-build-install-support, and data-generation engagements; some older deals also included milestone, royalty, or equity components.
Differentiators
Technology
Customers
Competitors
Estimated revenue
About $170.2M in FY2025 actual revenue; external estimates have ranged roughly from $100M-$250M.
Estimated monthly visits
13K
Traffic estimate as of May 2026
Ginkgo disclosed a reduction in force of roughly 35% of its workforce amid restructuring and cost-cutting.
SourceGinkgo announced it would sell/divest its biosecurity business to a consortium of investors, making it a standalone private entity.
SourceManagement said it would decommission the majority of traditional lab benches, walk-up automation, and workcells as it concentrates on autonomous labs.
SourceThe company reported significant restructuring, site consolidation, and an expanded cost-savings target, including excess space available for sublease.
Source